GRI Bio Presents Positive Preclinical Data on GRI-0621 for Treating Pulmonary Fibrosis at AFDD Summit

Quiver QuantitativeNov 21 08:50 ET

GRI Bio Highlights GRI-0621's Potential To Reduce Inflammation And Hepatic Fibrosis In Idiopathic Pulmonary Fibrosis, With Positive Preclinical Data Presented At AFDD Summit And Phase 2 Topline Data Expected In Q2 2025

BenzingaNov 21 08:46 ET

GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

GlobeNewswireNov 21 08:45 ET

Inflation Warning Sign? Old Dominion Freight Line Announces Rate Increase

Seeking AlphaNov 18 07:28 ET

12 Health Care Stocks Moving In Friday's Pre-Market Session

BenzingaNov 15 16:06 ET

Express News | GRI Bio Shares Are Trading Lower After the Company an Offer and Resale of up to 1,577,829 Shares by the Selling Stockholders. The Company Reported Q3 Financial Results

BenzingaNov 15 08:24 ET